Meet the Modern Day Cinderella
February 9, 2016
An exclusive interview with the talented actress starring as this reimagined heroine
With its fresh new take on the beloved tale of a young woman who is transformed from a chambermaid into a princess, this hilarious and romantic take on Cinderella combines the story’s classic elements – glass slippers, pumpkin, and a beautiful ball – along with some surprising twists.
More than just a pretty face with the right shoe size, this Cinderella is a contemporary figure living in a fairytale setting. She is a spirited young woman with savvy and soul who doesn’t let her rags or her gowns trip her up in her quest for kindness, compassion, and forgiveness. She longs to escape the drudgery of her work at home and instead work to make the world a better place. She is the Cinderella of the 21st century.
The Balancing Act correspondent, Amber Milt, takes viewers to Cleveland to meet Paige Faure, the talented actress starring as this reimagined heroine. In the behind-the-scenes interview, she explains how she balances the demands of her life on stage and off – raising her son on the road and performing eight times per week.
Don’t miss a second of this special episode of The Balancing Act, Thursday, April 21 and 28, 2016 at 7:30 a.m. (ET/PT). To purchase tickets to Cinderella, learn more about where the show is headed next and for even more exclusive content, go to www.BroadwayBalancesAmerica.com.
Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]
iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.
There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.